“We have received our Phase III clinical study report in Q1, and without delay in April, we initiated our NDA rolling submission to the FDA for Stargardt disease,” with CEO Yu-Hsin Lin (Chairman of ...
MarketBeat on MSN
Belite Bio Q1 earnings call highlights
Key Points Interested in Belite Bio, Inc. Sponsored ADR? Here are five stocks we like better. Belite Bio said it has started ...
Belite Bio, Inc (NASDAQ:BLTE) Chief Executive Officer Lin Yu-Hsin, has sold a total of 9,200 American depositary shares of the company on April 9, 2026, in a series of transactions. The sales were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results